Facebook icon Twitter icon
Antimicrobial Resistance, Oct 29-Nov 1, 2017, Santa Fe, NM, USA
Antimicrobial-resistant (AMR) infections claim hundreds of thousands of lives around the globe annually. This problem is exacerbated by a steady increase in global antimicrobial use and abuse in the clinic and agriculture, and a dearth of novel antimicrobials making it to market. If these scenarios continue unchecked, AMR will cumulatively cost the global economy at least 100 trillion dollars by 2050.

This three-day conference will focus on the latest work understanding and combatting AMR, incorporating clinical perspectives on AMR diagnostics and management, translational academic perspectives on design of drug regimens and combinations that suppress AMR, pharma perspectives on recent successes and failures in novel antimicrobial development and clinical trials, and basic science perspectives on the ecology and transmission of evolving AMR determinants. While these stakeholders are similarly motivated to identify and develop therapies to treat the exceptional, unmet medical need of worsening AMR, their spheres rarely overlap at scientific conferences, leading to scientific communication barriers between subject matter experts. This conference attempts to address this challenge by engaging diverse global perspectives on these topics, bringing together speakers and attendees from research academia, industrial drug development, and healthcare practice and policy. In summary, key goals are to:
  • Present and discuss the most current and cutting-edge results regarding understanding and combatting antimicrobial resistance, including presentation of the newest technologies, experimental approaches, and policy initiatives, as well as discussions of how to speed their translation and clinical implementation;
  • Address current controversies that may slow progress in the field, and consider future directions, including identification of the most pressing unanswered questions, the areas needing more focus, and those that would benefit from new approaches and methodologies;
  • Bridge the gap between scientists from the academic research arena, pharma/industrial drug development, and healthcare practice and policy.
Hear the following confirmed speakers (additional speakers will be added, including short talks chosen from abstracts):
Paul Ambrose, Institute for Clinical Pharmacodynamics, USA
Gavin Barlow, Hull and East Yorkshire Hospitals, NHS Trust and University of York, UK
Ilana L. Brito, Cornell University, USA
Carey-Ann D. Burnham, Washington University School of Medicine, USA
Karen Bush, Indiana University, USA
Lynn Connolly, Achaogen, USA
Gautam Dantas, Washington University School of Medicine, USA
Thomas F. Durand-Reville, Entasis Therapeutics, USA
Danica Galonic Fujimori, University of California, San Francisco, USA
Lorraine D. Hernandez, Merck Research Laboratories, USA
Kathryn E. Holt, University of Melbourne, Australia
Scott Hultgren, Washington University School of Medicine, USA
Ramanan Laxminarayan*, Center for Disease Dynamics, Economics and Policy, India
Jean Patel, Centers for Disease Control and Prevention, USA
Folkert Reck, Novartis Institutes for BioMedical Research, USA
Aileen Rubio, Spero Therapeutics, USA
Paolo Ruggerone, Università degli studi di Cagliari, Italy
Gerry D. Wright, McMaster University, Canada
Pamela Yeh, University of California, Los Angeles, USA
Helen I. Zgurskaya, University of Oklahoma, USA

*Keynote Speaker
Oct 29 – Nov 1, 2017
Eldorado Hotel
Santa Fe, New Mexico, USA

Scientific Organizers:
Gautam Dantas, Washington University School of Medicine
Jennifer A. Leeds, Novartis Institutes for BioMedical Research

Submit Abstract Apply for Scholarship
Submit Abstract Submit Abstract
Register Register


• Surveillance and Treatment of Resistant Bacterial Infections in Clinical Practice
• Workshop 1: Novel Therapeutic Strategies
• Fate and Lessons Learned from Recent Drug Development Programs Focused on Resistant Pathogens or Narrow-Spectrum Agents
• Alternative Approaches to Tackling Resistant Infections
• Multidrug Evolutionary Strategies to Invert Resistance Selection
• Ecology and Evolution of AMR Transmission Dynamics Across Habitats
• Workshop 2: Novel Strategies for AMR Discovery, Diagnostics and Modeling
• Tackling AMR – Challenges in Drug Development


Scholarship Application:
June 27, 2017

Discounted Abstract Submission:
June 27, 2017

Abstract Submission:
July 27, 2017

Discounted Registration:
August 29, 2017
Who should attend?
Biochemists • Clinicians • Drug Developers • Epidemiologists • Infectious Disease Specialists • Medicinal Chemists • Microbiologists

We thank PLOS for their in-kind marketing/advertising support of this meeting:

Additional Information
  • Click here to view the program and click here to download a program flyer.
  • Deadlines are at midnight US Mountain Time.
  • Discounted abstract submission and discounted registration save 50 USD and 200 USD, respectively, on later fees.
  • Presenting a poster is an excellent way to gain feedback on your work. Abstracts can be submitted through the discounted registration deadline for poster presentation, but those submitted by the abstract deadline will also be considered for short talk selection.
  • Please note that the first advertised meeting date is the date of arrival and registration, and the last date that of the last organized sessions.